To receive all Noxxon news in real time, contact [email protected]
Berlin, Germany, December 29, 2021, 6:00 p.m. CET – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), today announces the extension of the agreement with Atlas Special Opportunities, LLC (ASO) relating to the additional provision of a maximum of € 17 million in equity-related securities and the issue of 2,419 convertible bonds (including 44 convertible bonds issued related to transaction costs) for a total nominal value of € 2.419 million.